The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): A qualitative study.
 
Heather Gelhorn
Employment - Evidera
 
Sandra Tong
Employment - Plexxikon
Leadership - Plexxikon
Patents, Royalties, Other Intellectual Property - Plexxikon (Inst)
 
Grant Maclaine
Employment - BD Biosciences; Daiichi Sankyo
Stock and Other Ownership Interests - Ark Pharmaceuticals; BD Biosciences; Cochlear; Daiichi Sankyo; GE Healthcare (I); GlaxoSmithKline; ImpediMed; Lilly (I); Merck (I)
Consulting or Advisory Role - CryoLife
 
John H. Healey
No Relationships to Disclose
 
Susan V. Bukata
Honoraria - Amgen; Lilly; Merck
Consulting or Advisory Role - Amgen; Lilly; Merck
Speakers' Bureau - Lilly
 
Vicki Leigh Keedy
Consulting or Advisory Role - Threshold Pharmaceuticals; ZIOPHARM Oncology
Research Funding - CytRx Corporation; eleison pharmaceuticals; Janssen; medpacto; Merrimack; pfizer; Plexxikon; Threshold Pharmaceuticals; ZIOPHARM Oncology
 
Stephen Patrick Anthony
Honoraria - Spectrum Pharmaceuticals
Speakers' Bureau - Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Spectrum Pharmaceuticals
 
Andrew J Wagner
Consulting or Advisory Role - Novartis; Plexxikon
Research Funding - Astex Pharmaceuticals (Inst); Genentech (Inst); ImClone Systems (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Morphotek (Inst); Novartis (Inst); Sanofi (Inst)
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Caris Life Sciences; Cell Therapeutics; CerRx; EmergingMed; HTG, Inc.; Insys Therapeutics; McKesson; Medelis; Medical Prognosis Institute; Medtronic; SynDevRx; Targeted Genetics
Honoraria - Celgene; Cerulean Pharma; Clarion Healthcare; Daiichi Sankyo; Genentech; Immunomedics; International Genomics Consortium; McKesson; Novartis; OncoMed; Peregrine Pharmaceuticals; Precision Medicine Research Associates, LLC; Puma Biotechnology
Consulting or Advisory Role - 3-V Biosciences; AgencyRx; Agenus; Aileron Therapeutics; Alethia Biotherapeutics; Alpha Cancer Technologies; Arsia Therapeutics; Arvinas; Azaya Therapeutics; Bellicum Pharmaceuticals; Biological Dynamics; Biomarin; Bionomics; Bristol-Myers Squibb; Buhl Oncology; CanBas; Caris Life Sciences; Cavion; Cerulean Pharma; CTI; CytRx Corporation; Daiichi Sankyo; dalian wanchun biotechnology; DNAtrix; Esperance Pharmaceuticals; Five Prime Therapeutics; Formula Pharmaceuticals; Halozyme; HealthCare Pharmaceuticals; Horizon Discovery; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Immunomedics; Inform Genomics; Innate Pharma; Insys Therapeutics; Invivodata; Kinex; Lilly; Lixte Biotechnology; Lorus; MBC Pharma; Medelis; MediaPharma; Medical Prognosis Institute; Merus; miRNA Therapeutics; Momenta Pharmaceuticals; Nereus Pharmaceuticals; Novartis; Nucana; Oncology Venture; Oncolytics; Oncolyze; OncoMed; Pain Therapeutics; Peregrine Pharmaceuticals; Pharmacyclics; Pharmatech; Pledpharma; Precision Medicine Research Associates, LLC; Puma Biotechnology; RadioRx; Reflexion Medical; RenovoRx; Samsung; Samumed; Senhwa Biosciences; Superlab Far East; SynDevRx; TD2; Teva; Theravance; TNI Biotech; Tolero Pharmaceuticals; Toray Industries; Trovagene; Vaccinex; VidaCare
Research Funding - 3-V Biosciences (Inst); Abraxis BioScience (Inst); Agios (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Plexxikon (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
Travel, Accommodations, Expenses - Aileron Therapeutics; Bionomics; Caris Life Sciences; Celgene; Cell Therapeutics; Cerulean Pharma; Cylene; Daiichi Sankyo; DNAtrix; Five Prime Therapeutics; FORMA Therapeutics; Halozyme; Innate Pharma; Lilly; McKesson; Medical Prognosis Institute; miRNA Therapeutics; Novartis; Oncolytics; Partners Healthcare; Quintiles; RadioRx; Senhwa Biosciences; Vaccinex
 
Arun S. Singh
Honoraria - Biomarin
Travel, Accommodations, Expenses - Biomarin
 
Carlos Becerra
Speakers' Bureau - Celgene; Lilly
 
Jennifer Hanlon
Employment - Evidera
 
William Lenderking
Employment - Evidera
 
Lindsey Murray
Employment - Evidera
 
Henry H Hsu
Stock and Other Ownership Interests - Plexxikon
Consulting or Advisory Role - Plexxikon
Patents, Royalties, Other Intellectual Property - Plexxikon (Inst)
 
Paul S. Lin
Employment - Plexxikon
Leadership - Plexxikon
Patents, Royalties, Other Intellectual Property - Plexxikon
 
William D. Tap
Consulting or Advisory Role - Advaxis; Ariad; EMD Serono; Janssen; Plexxikon
Travel, Accommodations, Expenses - Boehringer Ingelheim
Other Relationship - Morphotek